Litchlab has officially launched its Click Chemistry Drug Delivery Technology Platform and CDMO Services, designed to provide integrated, high-efficiency solutions for next-generation conjugated drug systems including ADCs, nucleic acid delivery, multifunctional nanoparticles, and long-acting depots. This end-to-end platform spans molecular design, reaction development, scale-up, GMP manufacturing, and regulatory support to help accelerate clinical translation.
Once considered a laboratory tool, click chemistry has become a pillar of modern pharmaceutical engineering — praised for its bioorthogonality, high specificity, rapid kinetics, and modular design. With the global rise of ADC pipelines, RNA therapeutics, and long-acting biologics, click-enabled conjugation and scaffold-building are emerging as critical enablers for CDMO differentiation.
Copper-Catalyzed Azide–Alkyne Cycloaddition (CuAAC): Efficient, high-yield reaction for bioconjugates and payloads
Strain-Promoted Azide–Alkyne Cycloaddition (SPAAC): Metal-free, suitable for in vivo applications and biologics
Bioorthogonal Systems: TCO–Tetrazine, Thiol–ene, Oxime ligation for triggered release, reversibility, and stimuli-responsiveness
Proteins / Antibodies / Enzymes: For uniform ADC production and site-selective modifications
Nanocarriers (Liposomes, Polymers, Micelles): Surface functionalization for targeted delivery or stealth properties
RNA Molecules (siRNA/mRNA): Terminal conjugation with lipid anchors, PEGs, or cell-targeting ligands
Injectable Hydrogels: Click crosslinking to enable in situ gelling and controlled release scaffolds
Process Development: From batch to continuous flow and microfluidic-enabled conjugation
Reaction Optimization: Maximized yield, purity, and site-specificity with minimal side reactions
Scale-Up Flexibility: mg to multi-kg GMP batch production for preclinical and clinical needs
Comprehensive Analytics: SEC-MALS, HPLC, MS, UV-Vis, conjugation ratio, and site characterization
| Application | Click Chemistry Role |
|---|---|
| ADCs | Precise site-selective conjugation to improve DAR and efficacy |
| RNA Delivery | Terminal conjugation for targeting, half-life extension, endosomal escape |
| Long-Acting Peptides | PEGylation and depot-forming modifications |
| Theranostic Systems | Drug–imaging agent or drug–radioisotope click-linking for companion diagnostics |
| Injectable Hydrogels | In situ gelation through click crosslinking for localized therapy |
| Smart Nanoparticles | Ligand attachment, fluorescence labeling, multi-drug integration |
With 400+ ADC programs and 100+ RNA delivery therapeutics in the global pipeline, nearly 1 in 3 uses click-based conjugation to enable better stability, targeting, and modular design. Litchlab’s platform is built to serve this demand — providing scalable, regulatory-compliant, and innovation-driven solutions for tomorrow’s medicine.
📞 Let’s build the next generation of precision therapeutics — together.
🔗 Visit: www.litchlab.com
📧 Email: sales@litchlab.com
